CVST with thrombocytopenia reported after COVID-19 vaccine with adenoviral vector; management similar to heparin-induced thrombocytopenia
Blood Clot Risk High Following COVID-19 Hospitalization
However, anticoagulation cuts risk for major thromboembolic events by 46 percent
Prophylactic Anticoagulation May Cut COVID-19 Mortality
Lower 30-day mortality, no increase in serious bleeding events seen among COVID-19 inpatients receiving early prophylactic anticoagulation
Early Anticoagulation May Not Up Survival in Severe COVID-19
Venous thromboembolism seen in 6.3 percent and major bleeding seen in 2.8 percent of critically ill COVID-19 patients
Full-Dose Heparin May Aid Moderately Ill COVID-19 Patients
Interim results show improvement in primary end point of need for ventilation, other organ-supportive interventions
Anticoagulants Not Tied to Higher Risk for GI Bleed in COVID-19
3 percent of hospitalized COVID-19 patients experience gastrointestinal bleeding
Ongoing Anticoagulant Use Does Not Avert Severe COVID-19
No reduction seen in risks for hospital admission, intensive care unit admission, or death due to COVID
High-Dose Anticoagulation May Not Aid COVID-19 Patients
No significant benefit seen for high-dose versus standard anticoagulation therapies, may be harmful